ReviewCurrent treatment options in oncology2012
Adjuvant therapy of gastrointestinal stromal tumors (GIST).
Review in Current treatment options in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- An update on gastrointestinal stromal tumors (GISTs) with a focus on extragastrointestinal stromal tumors (EGISTs).Gastroenterology report · 2025Review
- CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor.Scientific reports · 2023Article
- Gastrointestinal stromal tumour masquerading as a diverticular bleed.BMJ case reports · 2019Article
- Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018Article
- Extra-Gastrointestinal Stromal Tumor of the Greater Omentum: Unusual Case Report.Journal of gastrointestinal cancer · 2016Article
- Evaluation of Gold's nomogram for predicting recurrence-free survival in gastrointestinal stromal tumors in Indian patients.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2016Article
- Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.Virchows Archiv : an international journal of pathology · 2015Article
- Peritonitis secondary to spontaneous perforation of a primary gastrointestinal stromal tumour of the small intestine: A case report and a literature review.International journal of surgery case reports · 2015Article
- Gastrointestinal stromal tumor: 15-years' experience in a single center.BMC surgery · 2014Article
- Considering the role of radiation therapy for gastrointestinal stromal tumor.OncoTargets and therapy · 2014Article
- Gastrointestinal stromal tumors.Gastroenterology clinics of North America · 2013Review
- Update on imatinib for gastrointestinal stromal tumors: duration of treatment.OncoTargets and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant period. Although observation for a longer follow-up is needed, attempts to prolong adjuvant therapy beyond the currently standard 3 years have been made and the results are awaited. However, the impact of more prolonged adjuvant intervals on secondary resistance is unknown, so that standard practice is still 3 years in most institutions. The adjuvant choice should be based on a rather precise identification of the relapse risk of the single patient, reserving treatment to the high-risk subgroups. The choice also should be personalized on the basis of genotype: generally, PDGFRA D842V mutated and wild-type GIST are excluded. Additional results from completed trials on a longer follow-up are awaited to further refine such "precision" decision-making. There are several instances in which part of the "adjuvant" treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer.
Indexed as
Identifiers
22743760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.